Initiating at Overweight: ELVN-001's 2L+ Entry Point ENABLEs Frontline Expansion Potential

We are initiating coverage on Enliven Therapeutics (ELVN) with an Overweight rating and a Dec-27 price target of $75. Our thesis centers on ELVN-001, a highly selective ATP-competitive BCR::ABL inhibitor, being a differentiated chronic-phase CML asset that can first address 2L+ post-allosteric patients and then expand into frontline patients. While asciminib's allosteric approach has improved tolerability and avoids many ATP-site resistance mutations, the emergence of myristoyl-pocket resistance creates a need for an ATP-competitive TKI, giving physicians an option to switch drug class for the subsequent line of therapy while preserving a well-tolerated safety profile. Enliven is well-positioned to become the treatment of choice for post-asciminib and frontline patients given its broad mutational coverage (including T315I) and retained activity against mutations associated with asciminib. We model U.S. peak sales of ~$5B+ across chronic-phase CML (roughly equal between frontline and 2L